Cost Effectiveness of First-Line Treatment with Doxorubicin/Ifosfamide Compared to Trabectedin Monotherapy in the Management of Advanced Soft Tissue Sarcoma in Italy, Spain, and Sweden

Table 1

Probabilities of receiving second-line treatments.

Regimen	Probability of receiving second-line treatment in
	Italy	Spain	Sweden
Following first-line treatment with doxorubicin/ifosfamide
CYVADIC^∧	<0.01	<0.01	0.10
Gemcitabine/dacarbazine	<0.01	0.12	<0.01
Gemcitabine/docetaxel	0.18	0.20	0.48
Gemcitabine/paclitaxel	<0.01	0.10	<0.01
Gemcitabine/vinorelbine	<0.01	0.08	<0.01
Gemcitabine monotherapy	<0.01	0.12	<0.01
Ifosfamide monotherapy	0.20	0.12	<0.01
Liposomal doxorubicin	0.12	<0.01	<0.01
Trofosfamide	<0.01	<0.01	0.12
Trabectedin monotherapy	0.50	0.26	0.30
Following first-line treatment with trabectedin monotherapy
Docetaxel monotherapy	0.26	<0.01	<0.01
Doxorubicin/ifosfamide	<0.01	<0.01	0.67
Doxorubicin monotherapy	<0.01	<0.01	<0.01
Gemcitabine/docetaxel	0.05	0.44	0.25
Ifosfamide/epirubicin	0.16	<0.01	<0.01
Ifosfamide monotherapy	0.53	0.56	<0.01
Trofosfamide/etoposide	<0.01	<0.01	0.08

 ^∧CYVADIC: cyclophosphamide, vincristine, adriamycin, and dacarbazine.